HSBC Holdings
ADVM

HSBC Holdings’s Adverum Biotechnologies ADVM Stock Holding History

HSBC Holdings’s Portfolio ADVM Stock Details ADVM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-10,704
Closed -$48.7K – 3012
2024
Q4 		$48.7K Sell
10,704
-4,026
-27% -$27.1K ﹤0.01% 2991
2024
Q3 		$103K Buy
+14,730
New +$107K ﹤0.01% 2793

Other funds holding ADVM

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PWA
Principia Wealth Advisory Dallas, Texas $160M AUM 37.01% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

HSBC Holdings's ADVM Position: Q1 2025 in Review

HSBC Holdings sold out of Adverum Biotechnologies (ADVM) in Q1 2025, closing a stake of 10,704 shares — an estimated $48.7K sold.

HSBC Holdings first reported a position in ADVM in Q3 2024 and held it in 2 quarters. The position peaked at $103K in Q3 2024. 70 funds tracked by Wall St. Rank hold ADVM as of Q1 2025.

  • HSBC Holdings reported no remaining Adverum Biotechnologies position as of Q1 2025 after selling out during the quarter.
  • HSBC Holdings sold 10,704 Adverum Biotechnologies shares in Q1 2025, an estimated $48.7K.
  • HSBC Holdings first reported a position in Adverum Biotechnologies in Q3 2024 and held it in 2 quarters.
  • HSBC Holdings's Adverum Biotechnologies position peaked at $103K in Q3 2024.
  • 70 funds tracked by Wall St. Rank held Adverum Biotechnologies as of Q1 2025.

Based on HSBC Holdings's 13F filing for Q1 2025, filed 14 May 2025.